Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients

J Clin Pharmacol. 2017 Jan;57(1):125-128. doi: 10.1002/jcph.788. Epub 2016 Jul 29.

C M Nijenhuis¹, A D R Huitema¹, C Blank², J B A G Haanen², J V van Thienen², H Rosing¹, J H M Schellens^{3

4}, J H Beijnen^{1

4}

¹ Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek/The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, The Netherlands.
² Division of Immunology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
³ Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁴ Division of Pharmacoepidemiology and Clinical Pharmacology, Faculty of Science, Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.

No abstract available

Keywords: LC-MS/MS; exposure-response; pharmacokinetics; routine clinical care; therapeutic drug monitoring; vemurafenib.

Publication types